Haiying Zhan, MD, PhD
Assistant Professor of PathologyCards
About
Research
Publications
2026
Histomorphologic analysis and clinical correlation of atypical apocrine lesions in breast pathology
Podany P, Zhan H, Colón-Cartagena L, Ai D, Du J, Krishnamurti U, Liang Y. Histomorphologic analysis and clinical correlation of atypical apocrine lesions in breast pathology. Human Pathology 2026, 175: 106158. PMID: 42176994, DOI: 10.1016/j.humpath.2026.106158.Peer-Reviewed Original ResearchAtypical apocrine lesionsInvasive ductal carcinomaApocrine lesionsNuclear irregularityCribriform architectureDuctal carcinomaHistological featuresClinical correlatesBreast pathologyNuclear enlargementClinical follow-up dataAtypical ductal hyperplasiaFollow-up dataApocrine hyperplasiaDuctal hyperplasiaPatient ageNo significant differenceClinical outcomesApocrine adenosisApocrine changeClinical differencesClinical significanceNuclear featuresLesion sizeUpstagingPathological response to herceptin-containing neoadjuvant therapy in HER2 IHC2+/ISH+ and IHC3+ early-stage invasive ductal carcinoma
Jordan T, Chan N, Rimm D, Zhan H. Pathological response to herceptin-containing neoadjuvant therapy in HER2 IHC2+/ISH+ and IHC3+ early-stage invasive ductal carcinoma. Human Pathology 2026, 173: 106121. PMID: 41985721, DOI: 10.1016/j.humpath.2026.106121.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAntibodies, Monoclonal, HumanizedAntineoplastic Combined Chemotherapy ProtocolsBiomarkers, TumorBreast NeoplasmsCarcinoma, Ductal, BreastFemaleHumansImmunohistochemistryIn Situ Hybridization, FluorescenceMiddle AgedNeoadjuvant TherapyNeoplasm StagingNeoplasm, ResidualPathologic Complete ResponseRetrospective StudiesTrastuzumabTreatment OutcomeConceptsInvasive ductal carcinomaRecurrence-free survivalResidual cancer burdenEarly-stage invasive ductal carcinomaIHC 3HER2 copy numberPathological responseNeoadjuvant therapyHER2/CEP17 ratioDuctal carcinomaHormone receptor-positive casesInferior recurrence-free survivalResidual cancer burden classResponse to neoadjuvant therapyHER2-positive breast cancerReceptor-positive casesKaplan-Meier analysisPCR rateER-/PR-Pretreatment biopsiesHER2 expressionClinicopathological parametersCopy numberRecurrence rateTherapeutic stratificationDiagnosis of Ductal Carcinoma in Situ in Breast Biopsies for a Radiological Mass Lesion: Did We Miss Something?
Theriot J, Zhan H, Colón-Cartagena L, Lotfi P, Krishnamurti U, Liang Y. Diagnosis of Ductal Carcinoma in Situ in Breast Biopsies for a Radiological Mass Lesion: Did We Miss Something? International Journal Of Surgical Pathology 2026, 10668969261436010. PMID: 41944434, DOI: 10.1177/10668969261436010.Peer-Reviewed Original ResearchMass-forming lesionsInvasive carcinomaMass lesionPapillary carcinomaStromal fibrosisHistological subtypesHistological predictorsNuclear gradeHistopathological featuresEstrogen receptorPredictors of invasive carcinomaDiagnosis of ductal carcinomaPresence of invasive carcinomaCarcinoma in situSolid papillary carcinomaNon-invasive tumorsPathologic-radiologic correlationPapillary DCISDuctal carcinomaSurgical outcomesBenign lesionsBreast biopsyImaging findingsDCISHistological featuresClinicopathologic Analyses of 34 Cases of High-Grade Serous-Like Carcinoma (HG-SL-Ca) of the Breast
Haw Y, Krings G, Hsiao W, Zhan H, Hou Y, Zhang G, Zhang H, Wei S, Yang W, Laé M, Post M, Liu Y, Shamir E, Rosa M, Siziopikou K, Schnitt S, Chen Y, Li X. Clinicopathologic Analyses of 34 Cases of High-Grade Serous-Like Carcinoma (HG-SL-Ca) of the Breast. The American Journal Of Surgical Pathology 2026, 50: 543-549. PMID: 41735183, DOI: 10.1097/pas.0000000000002516.Peer-Reviewed Original ResearchPathological complete responseAberrant p53 expressionLocal recurrenceTumor sizeP53 expressionAssociated with shorter metastasis-free survivalPathologic complete response rateAssociated with worse overall survivalAxillary lymph node metastasisShorter metastasis-free survivalER-/HER2+GATA-3 stainingWell-formed tubulesMetastasis-free survivalLymph node metastasisFollow-up dataER+/HER2+Nuclear WT1ER-/HER2-Complete responseNeoadjuvant chemotherapyDistant metastasisOverall survivalNuclear gradeBreast carcinomaQuantitative Assays for TROP2 Measurement in Breast Cancer and Comparison to H-Score
He M, Chan N, Liu M, Robbins C, Bates K, Benanto J, Colón-Cartagena L, Kahila M, Zhan H, Krishnamurti U, Moutafi M, Yaghoobi V, Liebler D, Fulton R, Rimm D. Quantitative Assays for TROP2 Measurement in Breast Cancer and Comparison to H-Score. Applied Immunohistochemistry & Molecular Morphology 2026, 34: 143-154. PMID: 41709478, PMCID: PMC13143368, DOI: 10.1097/pai.0000000000001311.Peer-Reviewed Original ResearchTrophoblast cell surface antigen 2Trophoblast cell surface antigen 2 expressionH-scoreBreast cancerQuantitative immunofluorescenceSacituzumab govitecanPathologists' readingsTNBC cohortAntibody-drug conjugate targetsExpression of trophoblast cell surface antigen 2H-score methodSolid tumor typesBreast cancer cohortBreast cancer biopsiesYale-New Haven HospitalBreast cancer samplesCompanion diagnostic testsSurface antigen 2H-score assessmentTumor typesClinical outcomesNew Haven HospitalCancer biopsiesTumor samplesCancer cohort
2025
Mixed Molecular Subtypes Coexist in Estrogen Receptor Heterogeneous Primary Breast Cancers
Foldi J, Xiong K, Liu M, Robbins C, Chen F, Zhan H, Burela S, Dai J, Karn P, Dugo M, Bianchini G, Lee A, Oesterreich S, Rimm D, Pusztai L. Mixed Molecular Subtypes Coexist in Estrogen Receptor Heterogeneous Primary Breast Cancers. JCO Precision Oncology 2025, 9: e2500529. PMID: 41237360, DOI: 10.1200/po-25-00529.Peer-Reviewed Original ResearchConceptsPrimary breast cancerBreast cancerMolecular subtypesClinical outcomesEstrogen receptor (ER)-negativeClinical outcomes of patientsHigh recurrence scoreOutcomes of patientsTumor cell populationDigital spatial profilingMolecular featuresER-highER-lowPreoperative chemotherapyER-negativeER-positiveRecurrence scoreER expressionEndocrine-resistantEndocrine resistanceChemotherapy strategiesChemotherapy sensitivityIntratumoral heterogeneityPositive cellsER heterogeneityInvasive breast carcinoma in a patient with PHTS: a case report
Zhan H, Fischbach N, Lynch M, Liang Y, Krishnamurti U, Cohen P. Invasive breast carcinoma in a patient with PHTS: a case report. Diagnostic Pathology 2025, 20: 120. PMID: 41107919, PMCID: PMC12532417, DOI: 10.1186/s13000-025-01715-1.Peer-Reviewed Original ResearchConceptsPTEN hamartoma tumor syndromeAtypical ductal hyperplasiaHamartoma tumor syndromeTumor syndromeFamily historyBilateral palpable breast massesFocal atypical ductal hyperplasiaFamily history of cancerInvasive breast carcinomaPalpable breast massesEctopic breast tissueBloody nipple dischargeAxillary lymph nodesGermline pathogenic variantsHistory of cancerCase presentationWeInvasive carcinomaBreast carcinomaDuctal hyperplasiaMastectomy specimensNipple dischargeRight breastBenign papillomasMultiple biopsiesPapillary proliferationPredicting the Probability of Residual Axillary Nodal Metastases in Patients With Breast Cancer Treated With Neoadjuvant Chemotherapy
Khoury T, Zhan H, Huang X, Ghasemi F, Rajack F, Yuan G, Yu H, Theriot J, Bragiel R, Okamoto K, Ali M. Predicting the Probability of Residual Axillary Nodal Metastases in Patients With Breast Cancer Treated With Neoadjuvant Chemotherapy. Modern Pathology 2025, 38: 100902. PMID: 41043643, PMCID: PMC12624850, DOI: 10.1016/j.modpat.2025.100902.Peer-Reviewed Original ResearchConceptsAxillary lymph node dissectionSentinel lymph node metastasisSentinel lymph nodeResidual axillary diseasePositive lymph nodesAxillary diseaseNegative lymph nodesNeoadjuvant chemotherapyLymph nodesLymphovascular invasionHistological typeIndependent predictorsBreast cancer treated with neoadjuvant chemotherapyPatients treated with neoadjuvant chemotherapyCompletion axillary lymph node dissectionPositive sentinel lymph nodeNeoadjuvant chemotherapy settingPositive SLN biopsyAxillary nodal metastasesLymph node dissectionResidual cancer burdenNegative predictive valueArea under the curveValidation setTreatment effectsInterobserver agreement and histologic analysis of atypical ductal hyperplasia bordering on ductal carcinoma in situ: A multi-institutional study
Korie U, Ai D, Podany P, Zhang H, Zhan H, Kahila M, Colon-Cartagena L, Wei S, Sun H, Du J, Krishnamurti U, Liang Y. Interobserver agreement and histologic analysis of atypical ductal hyperplasia bordering on ductal carcinoma in situ: A multi-institutional study. American Journal Of Clinical Pathology 2025, 164: 704-711. PMID: 40994034, DOI: 10.1093/ajcp/aqaf088.Peer-Reviewed Original ResearchConceptsDuctal carcinoma in situAtypical ductal hyperplasiaCarcinoma in situSpindle-shaped nucleiAssociated with carcinomaIndividual histologic featuresHistological featuresInterobserver agreementDuctal hyperplasiaBreast pathologistsBiopsy casesCases of atypical ductal hyperplasiaLow-grade ductal carcinoma in situEpithelial cellsClinical follow-up dataLesion extentHistological analysisDiagnostic gray zoneMulti-institutional studyVariable interobserver agreementFollow-up dataModerate to substantial agreementDuct involvementHistologic reviewRadiological findingsEstrogen receptor conversion in bone, liver and lung metastases from breast cancer
Podany P, Zhan H, Ai D, Krishnamurti U, Liang Y. Estrogen receptor conversion in bone, liver and lung metastases from breast cancer. Pathology - Research And Practice 2025, 275: 156222. PMID: 40967162, DOI: 10.1016/j.prp.2025.156222.Peer-Reviewed Original ResearchER conversionPrimary tumorTumor gradeGrade of primary tumorAssociated with worse prognosisMetastasis to boneBreast cancer treatmentMetastatic sitesER-positiveMedian survivalTP53 mutationsLiver metastasesPR positivityPIK3CA mutationsReceptor conversionClinicopathological factorsLung metastasesWorse prognosisNo significant differenceTumor typesBreast cancerGenetic alterationsMetastasisPatient managementTumor